The discovery of leptin was a landmark event in modern physiology. Leptin is a hormone derived from fat that informs the brain about the status of energy stores in peripheral tissues, and its discovery closed a physiologic feedback loop that was long hypothesized to control normal energy homeostasis. Now, the Albert Lasker Basic Medical Research Award is recognizing the researchers who produced this breakthrough, Douglas Coleman at The Jackson Laboratory and Jeffrey Friedman at The Rockefeller University and the Howard Hughes Medical Institute.
Although the contributions of the two awardees differed in approach and occurred three decades apart, their joint recognition reflects the essential contributions that each researcher made to this field-changing discovery. Doug Coleman is recognized for demonstrating that a ''satiety factor'' circulating in the blood stream was absent in a mutant mouse strain (ob/ob) that is severely obese and for correctly predicting that the hypothalamus is the target of this factor. Stimulated by Coleman's results, Jeffrey Friedman took up the ambitious goal of cloning the genes mutated in the mouse strain at a time when such a feat was extremely difficult. He found that the ob gene encodes a protein hormone that reverses obesity and metabolic abnormalities in the ob/ob mice. These discoveries revised our understanding of integrative metabolism and set the stage for explosive and still accelerating research efforts in numerous fields.
Background History
Sometimes in science, a single breakthrough changes a field in such a dramatic way that newcomers to the field have difficulty appreciating the ''landscape'' of the research prior to the discovery. This is surely the case for the field of energy balance regulation before and after the discovery of leptin. Even 30 years before leptin's discovery, a substantial body of evidence suggested that energy intake and expenditure were tightly regulated. For example, when animals were forcibly overfed (or starved) and then returned to their original diets, they reliably and often quite precisely returned to their initial weights. Clearly, a physiologic homeostatic system of some type was in play. Furthermore, it was known that small lesions in the hypothalamus caused either obesity or leanness in humans and mice by disrupting food intake and possibly energy expenditure. For some scientists, these results suggested that regions within the hypothalamus might be master regulators of energy balance, integrating signals from peripheral organs that reflect the energy status of the organism and then engaging pathways to adjust nutrient intake and energy expenditure to maintain homeostasis.
Experimental support for this concept emerged slowly. In 1959, the British physiologist William Hervey published a prescient study reporting the results of surgically joining normal rats with those given lesions in the ventromedial Together, Douglas Coleman (left) and Jeffrey Friedman (right) discovered the hormone leptin, which signals to the brain the state of energy stores in peripheral tissues. hypothalamus (VMH), which were known to cause obesity (Hervey, 1959) . In these ''parabiotic'' experiments, Hervey connected the rats through their subcutaneous tissues, permitting a low-rate exchange of extracellular and bloodborne elements from one animal to the other. Although Hervey was not the first researcher to employ this experimental model, the surgical unions between these particular rats generated a particularly interesting result.
As expected, the rats with VMH lesions became obese. Surprisingly, however, the normal rats ingested far less food than usual and lost substantial weight when they were joined to the obese rats. Based on these results, Hervey postulated that the VMH normally responds to a satiety signal that regulates feeding. Without a functional VMH, the rats could not respond to this signal; they became obese and then overproduced the satiety signal, which Hervey postulated was a peripheral factor. Furthermore, Hervey surmised that high levels of this signal crossed over into the circulation of the normal rats, suppressing their food intake and weight.
Remarkably, this hypothesis proved to be correct. However, given the complexity of the parabiotic model used in the study, more pedestrian explanations might easily have accounted for the decreased food intake of the normal rats. Plus, identifying a hypothesized hormone from an unknown site was a daunting task, which led many in the field to look elsewhere for interesting experiments to pursue. Despite much speculation and the suggestive evidence from this study and related approaches, no convincing proof had emerged for the existence of a specific physiologic system that controls energy intake, energy expenditure, and body weight when Douglas Coleman began to tackle the problem over the next decade.
Coleman Connects the Dots Douglas Coleman obtained a doctorate in biochemistry at the University of Wisconsin and took his first position at The Jackson Laboratory in Bar Harbor, Maine in 1958, where he expected to remain for only a couple of years to extend his understanding of genetics. Instead, he spent his entire career at The Jackson Laboratory until he retired in 1991. At the beginning, his research focused on muscle disorders in mice. However, his most notable accomplishments occurred while studying mice with genetic syndromes of obesity and diabetes, and at the time, The Jackson Laboratory was fertile soil for sowing such studies.
In 1949, an autosomal recessive syndrome of severe obesity appeared spontaneously in a colony of mice at The Jackson Laboratory. The mutation mapped to chromosome 6 and was designated obese (ob). In 1966, Coleman and his associates identified a second obesity syndrome with very similar symptoms, but this mutation, designated diabetes (db), mapped to chromosome 4 (Hummel et al., 1966) . Mice homozygous for both of these mutations demonstrated dramatic early onset obesity, insulin resistance (with varying severity of diabetes), infertility, and a variety of other symptoms, including hyperphagia (i.e., overeating) and decreased locomotor activity. Of interest, when the mutations were bred onto strains with different genetic backgrounds, the mice displayed substantial phenotypic variation in several features, including the presence of overt diabetes. The Coleman lab carried out extensive mouse breeding and phenotyping experiments in an effort to understand how the genetic background regulates these metabolic phenotypes, an important but still largely unresolved question.
Coleman's most important observations, however, came from a series of parabiosis experiments with the mutant animals. When the subcutaneous tissues of ob/ob mice were surgically connected to that of either wild-type or db/db animals, the ob/ob mice decreased feeding and lost weight, and this effect reversed when the union was ended. Control mice were unaffected by the union with ob/ob mice (Coleman, 1973) . In contrast, when normal mice were parabiosed to db/db mice, control mice stopped eating and lost substantial amounts of weight, but the db/db mice were unaffected. These results led Coleman to conclude correctly that ob/ob mice lacked a satiety factor in their blood stream that regulates feeding and weight. Although both the control and db/db mice supplied this factor to the ob/ob mice, the db/db mice did so more robustly. Coleman, therefore, speculated that db/db mice overproduced the circulating factor to which they could not themselves respond but which could be parabiotically transferred to other animals to regulate feeding and weight.
Aware of the experiments by Hervey (1959) , Coleman surmised that the hypothalamus probably contained the center that responds to the circulating factor. As with conclusions from Hervey's studies, Coleman's hypothesis proved to be right on target. However, in the absence of an identified circulating factor, many physiologists and obesity investigators continued to reserve judgment about the ultimate validity of the Coleman hypothesis, just as they did with Hervey's conclusions. Nevertheless, some daring investigators pursued this hypothesis and sought to biochemically purify and identify a factor from fat or other tissues that regulates food intake. This approach, although rational, did not succeed. For a quarter of a century after Coleman's insightful experiments, researchers identified neither a specific factor, its site of origin, nor its site of action. In fact, many leaders of the field questioned whether the efforts to find such a factor were scientifically justified.
Friedman Finds the Genes
Enter Jeffrey Friedman, two decades after Coleman's work. Trained as a physician, Friedman initially intended to become a gastroenterologist. However, the emerging power of molecular genetics lured him into a basic science laboratory to study physiology and disease. Working at The Rockefeller University, where he obtained a PhD in the laboratory of James Darnell Jr., Friedman became interested in the genetics of body weight regulation and decided to tackle the daunting task of cloning the ob gene. Initially in collaboration with other obesity researchers at Rockefeller, including Rudolph Leibel, Friedman methodically attacked this goal and ultimately accomplished it. The results led to insights that were nothing short of breathtaking.
In a classic 1994 Nature paper, Friedman and colleagues described the ob gene as a 4.5 kb transcript expressed exclusively in adipose tissue and predicted to encode a secreted peptide with 167 amino acids (Zhang et al., 1994) . Moreover, the transcript was disrupted in both available ob alleles. Soon after this initial paper, the Friedman group and two others laboratories demonstrated that treating ob/ob mice with the recombinant peptide dramatically corrected the animal's obesity and hyperphagia (Halaas et al., 1995) . Thus, the peptide was named ''leptin'' from the Greek root leptos for ''thin.'' Leptin was considerably more potent when injected directly into the CNS than into the blood stream, suggesting that the primary target of leptin is in the CNS, as Coleman predicted. Furthermore, leptin failed to act in db/db mice, which nicely ruled out a nonspecific basis for the weight loss and confirmed Coleman's hypothesis about the db/db mice lacking the ability to detect the circulating satiety factor. Thus, after almost a half a century of searching, the biochemical cause of obesity of the ob/ob mouse was finally understood.
In work that soon followed, the Friedman laboratory and one other group found that the db locus encodes a family of leptin receptors that are alternatively spliced and members of the cytokine receptor family (Lee et al., 1996) . The db allele altered only a single splice variant that, unlike the other variants, is expressed strongly in the hypothalamus. This variant was also the only leptin receptor predicted to mediate signaling through the Jak/Stat pathway. Not surprisingly, the Friedman laboratory soon demonstrated that leptin activates STAT3 in the hypothalamus when it is systemically administered (Vaisse et al., 1996) . Furthermore, selectively deleting this leptin receptor variant from neurons recapitulates the major features of the ob/ob syndrome.
Together, these findings demonstrated the existence of a previously unknown endocrine system through which the status of energy stores in fat is communicated by the hormone leptin to regulatory centers in the brain. Absence of either the ligand or the receptor caused severe and similar obesity syndromes, revealing the critical importance of this pathway and its potential relevance to human disease. Needless to say, this discovery transformed the field of nutritional metabolism.
Leptin Research Today
Over the ensuing 15 years, researchers have learned much more about the biology and pathophysiology of leptin.
Indeed, a PubMed search for ''leptin'' reveals more than 18,000 citations. The major developments in this intensive area of research can be grouped into three areas: the physiologic role of leptin; how leptin's action is limited in human obesity induced by diet or the environment; and the neural and peripheral circuits upon which leptin acts.
Initially, leptin was thought of as a molecule produced by excess adipose tissue to provide a negative feedback signal to the brain to limit obesity by reducing appetite and increasing energy expenditure. However, new data and physiologic thinking have substantially extended this initial understanding. Clearly, leptin reverses the syndrome of ob/ob mice, and recombinant leptin has equally dramatic effects on obese humans with rare loss-of-function mutations in the leptin gene (Farooqi et al., 1999) . However, disappointingly, both mice and humans with more common forms of obesity typically have high levels of leptin, and more importantly, their body weights respond weakly or not at all to pharmacologic supplementation of leptin (Heymsfield et al., 1999) . This suggests that ''common obesity'' is a state of leptin resistance, as opposed to leptin deficiency.
Of interest, obesity has long been known to be a state of resistance to insulin, the preeminent metabolic hormone. Numerous studies have characterized the molecular mechanisms and implications of insulin resistance associated with obesity. In obese patients, raising already high levels of insulin even further with exogenous doses typically lowers blood glucose, revealing that the resistance to insulin action on blood glucose is relative, not absolute. In contrast, raising leptin levels even further in the obese state has minimal effects on body weight, suggesting that leptin resistance to this important endpoint is almost absolute. Consequently, the identification of the molecular mechanisms underlying leptin resistance is a central question to address if we are to understand the pathophysiology of obesity as it occurs in most people.
Studies in mice have identified two likely mediators of leptin resistance. The most well-characterized one, suppressor of cytokine signaling 3 (SOCS3) (Bjørbaek et al., 1998) , is an intracellular inhibitor of Jak/Stat signaling. Leptin acutely induces expression of SOCS3 in target neurons, and SOCS3 expression is also increased in the hypothalamus of mice with dietinduced obesity. Most decisively, disrupting the function of SOCS3 enhances leptin signaling and limits obesity when susceptible mice are placed on diets that cause obesity (Howard et al., 2004) . A second candidate for an inhibitor of leptin signaling is the tyrosine phosphatase PTP1b. As with SOCS3, disrupting PTP1b protects against diet-induced obesity (Zabolotny et al., 2002) .
The most critical leptin signals are exerted in the hypothalamus. The hypothalamus cannot be probed experimentally in humans, and thus, our capacity to assess the roles of SOCS3 and PTP1b in human obesity is currently limited. Until approaches are identified to counter these inhibitory pathways, the existence of leptin resistance in humans will limit the therapeutic potential of leptin. Nevertheless, researchers are still actively searching for obese individuals that respond to leptin alone or in combination with other therapies.
It seems likely that leptin will also have therapeutic potential in disorders distinct from obesity. Several states of ''low leptin'' are associated neither with obesity nor with mutations of the leptin gene. For example, leanness and low body fat can cause low levels of leptin in women athletes, leading to amenorrhea and anovulation, and leptin supplementation may restore reproductive capacity in these cases (Welt et al., 2004) . In patients with syndromes of ''lipodystrophy,'' multiple causes lead to a deficiency of adipose tissue and thus leptin. Treatment with leptin dramatically improves fatty liver and insulin resistance in these patients (Petersen et al., 2002) .
Although a threshold of leptin action is clearly required for preventing severe obesity, this ''anti-obesity'' function paradoxically may not be the singular or even dominant physiologic role of leptin. Leptin levels rise in obesity, consistent with leptin's function as a negative feedback signal of energy stores. However, leptin expression and circulating levels fall quickly when normal mice and humans are starved. May leptin be a signal for adapting to starvation, as well as a signal for resisting excessive weight gain?
In addition to increased hunger, starvation induces a specific array of adaptive endocrine and metabolic consequences, including, most prominently, the suppression of reproductive capacity and decreased thyroid function. Importantly, these changes are severely blunted when leptin levels are kept constant by exogenous supplementation during starvation of mice (Ahima et al., 1996) . This finding led to the hypothesis that falling leptin is the dominant signal for initiating a broad program of adaptation to starvation. Indeed, the predicted impairments of endocrine function during starvation are also seen in ob/ob mice, such that these mutant mice are actually experiencing the physiology of starvation despite their severe obesity. We now understand that these two faces of leptin, mediating both the response to starvation as levels fall and the response to overfeeding as levels rise, represent the full range of leptin biology. In 1998, we hypothesized that leptin resistance of weight regulatory pathways during periods of energy excess provides an evolutionary advantage; it limits the capacity of leptin to keep an individual excessively lean, which would cause a more rapid demise during periods of food deprivation.
The discovery of leptin has also provided a powerful tool to explore the central neural circuits that control energy balance and related physiologies. A new era in the neurobiology of energy balance has been ushered in by the localization of leptin receptors in specific regions of the hypothalamus and the characterization of the leptin's ability to modulate expression of neuropeptides involved in regulation of appetite and body weight. Researchers have demonstrated that leptin reduces expression of several neuropeptides that potently stimulate feeding, such as Neuropeptide Y (NPY), Agouti-related protein (AgRP), and melanin concentrating hormone (MCH). Conversely, leptin administration stimulates expression of neuropeptides that suppress feeding and weight. For example, when neurons expressing proopiomelanocortin (POMC) are stimulated by leptin, they produce the neuropeptide aMSH, which stimulates central melanocortin 4 receptors on downstream neurons. The consequence of this stimulation is to suppress food intake and body weight. The critical relevance of this melanocortin circuit is evident not only from its identity as a target of leptin activation, but also from the fact that loss of function of the cognate melanocortin 4 receptor is the most common genetic cause of human obesity, accounting for 3%-5% of severe obesity in humans. Leptin also has direct and indirect actions in brain regions apart from hypothalamus, and it is clear that the full integrated circuitry of leptin action in brain will require much additional research.
Conclusions
What lessons can we learn from the discovery of leptin? First, indirect arguments or data supporting the existence of a physiologic system can be heuristically important and can serve as strong stimuli to drive groundbreaking research. Nevertheless, no matter how compelling, such arguments are often unconvincing to the scientific community until the specific molecules underlying the physiology are identified. Second, the discovery of a powerful regulator of appetite, energy balance, and body weight can still leave many outstanding questions about the mechanisms underlying disorders of body weight in humans. This can frustrate efforts to translate the discovery into an effective therapy for common forms of obesity. Finally, we should take note of the fact that both The Rockefeller University and Howard Hughes Medical Institute believed in Jeff Friedman's research project and supported his efforts during many years of hard work when tangible results were few and far between. The ability to make such long-term bets on people and their projects is difficult for funding agencies and institutions. We should celebrate the cases in which such confidence and support is given, especially when the researchers are successful and prove that the outcome was well worth the risk, as was the case here.
